Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis
Antibodies, Monoclonal, Murine-Derived
Granulomatosis with Polyangiitis
Current treatment regimens are largely successful in controlling AAV, but in approximately one-fourth of patients, active disease persists or recurs in the first 6 months despite treatment. PR3-ANCA positivity is a risk factor for recurrence or persistence of severe disease. ANCA titers and B cell detectability are poor predictors of both disease relapse and disease quiescence in the first 6 months.